
# **Biological Chemistry**



## **Table of Contents**

Scope and general policies of the journal2			
Article categories published Peer review, turnaround times and preprint policies			
Peer review, turnaround times and preprint policies	2		
Peer review information	2		
Turnaround time			
Appeals			
Preprint policy	2		
Inclusive language policy	2		
Submission of manuscripts	2		
ORCID	3		
Submission declaration and verification	3		
Scientific misconduct			
Research integrity	ວ		
Post-acceptance	3		
Galley proofs	ວ		
Offprints			
Repository policy	4		
Subscription-based and hybrid journals	4		
Note for authors of NIH-funded research			
Copyright	4		
Open Access in hybrid journals	4		
Open Access and Research Gate	4		
Article Processing Charges (APCs)	4		
Ethical conduct of research	5		
Acknowledgments	5		
Authorization for the use of human subjects – research ethics	5		
Authorization for the use of experimental animals – research ethics	5		
Author contributions			
Competing interests	6		
Research funding	6		
Data availability	6		
Database submissions			
Preparation of manuscripts			
Language	6		
General format and manuscript elements	6		
Title page information	7		
Abstract			
Keywords			
Sections			
References			
Figures and figure captions			
Tables and table captions	8		
Abbreviations	Q		
Equations and symbols			
Scientific names and non-abbreviated Latin expressions	Q		
Nomenclature			
Units			
Audio and Video			
Appendices			
Supplementary material	9		
Author short biography and photograph	9		

## Scope and general policies of the journal

*Biological Chemistry (Biol Chem)* provides rapid publication for reports on molecular studies of exceptional biological interest. The Journal publishes full-length papers, short communications, reviews and minireviews. Reviews are published by invitation only, but suggestions to the Editor-in-Chief are welcome.

## Article categories published

- Research Article
- Review Article
- Minireview
- Short Communication

## Peer review, turnaround times and preprint policies

#### Peer review information

*Biol Chem* is a single-blind peer reviewed journal. Manuscripts are reviewed anonymously by at least two independent reviewers selected by the Editors. The authors must provide the names and e-mail addresses of four potential reviewers upon submission. Reviewers indicated by the authors should be of institutions and countries different from those of any of the authors. Authors may also provide names of reviewers they wish to exclude from reviewing their manuscripts.

The Editors reserve the right to reject submitted manuscripts without peer review if the studies are not novel or important enough to merit publication in the journal. Manuscripts deemed unsuitable (insufficient originality or limited interest to the target audience) will be also rejected without review.

#### **Turnaround time**

*Biol Chem* aspires to inform authors of the editorial decision within 4 weeks from the submission date. Revised manuscripts should be returned within 2 months. Accepted articles are published online within 3–4 weeks of acceptance. Articles are first published online as DOI-citable paper, and later assigned to an issue with page numbers.

#### **Appeals**

Manuscripts that have been rejected for publication will be reconsidered only at the discretion of the Editor(s). Authors wishing to request reconsideration of a previously rejected manuscript must do so in written form and submit a rebuttal by e-mail to the journal's Editorial Office. Authors should provide detailed reasons why they believe the manuscript should be reconsidered. If the rebuttal is accepted, the author will be asked to re-submit the manuscript, or the decision will be reversed.

#### **Preprint policy**

De Gruyter does not consider the following purposes of a paper as pre-publication: publication in the form of a conference abstract, publication as an academic thesis, publication as an electronic preprint on recognized servers such as arXiv, RePEc, bioRxiv, ResearchSquare, etc.

#### **Inclusive language policy**

Inclusive language recognizes diversity, conveys respect for all people, is sensitive to differences and promotes equal opportunities. Content should not make assumptions about readers' beliefs or commitments; should not contain anything that might suggest that a person is superior to another because of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and should use inclusive language throughout. Authors should ensure that their writing is free from prejudice, stereotypes, slang, references to the dominant culture and/or cultural assumptions.

## **Submission of manuscripts**

Submit manuscripts exclusively online at: https://mc.manuscriptcentral.com/bc

Submitting authors must provide an ORCID number for successful submission (see below). Furthermore, the submitting and corresponding author(s) of each manuscript are required to register with institutional e-mail

addresses; private e-mail addresses will not be accepted. Submissions which are not compliant will be returned to the authors for amendment. A cover letter must be submitted for each manuscript upon first submission. It should contain a brief statement by the authors as to the element of novelty upon which they base their request for publication in *Biol Chem.* Please address the cover letter to the Editor-in-Chief. Revised manuscripts must be accompanied by a point-by-point reply to the reviewers' criticisms. Major changes in the revised manuscript must be highlighted, preferably in tracked changes mode. A second, unmarked version should always be submitted for major changes.

#### **ORCID**

The ORCID (Open Researcher and Contributor ID) is a non-profit, publisher-independent system that is used to uniquely identify academics and their publications. Click <a href="here">here</a> for detailed information about ORCID. Submitting authors can login with username and password, or with their ORCID number. Providing an ORCID number for each author of a manuscript is recommended; ORCID numbers should be listed on the title page.

#### Submission declaration and verification

For information on plagiarism, please refer to <u>COPE – Committee of Publication Ethics</u>. Submission of a manuscript to *Biol Chem* implies that the work described has not been published previously, except in the form of an abstract, academic thesis, lecture, or preprint; that it is not under consideration for publication elsewhere (multiple, redundant, concurrent publication); that publication of the work is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out; and that, if accepted for publication, it will not be published elsewhere, no matter in which language, without the written consent of the Publisher. Exceptions are listed under Preprint policy.

To exclude potential overlap with prior publication(s), your manuscript may be checked by the plagiarism detection tool "Crossref Similarity Check" (iThenticate). Previously published material must be referenced appropriately in the manuscript, regardless of whether the material was previously published in a subscription based, hybrid or open access journal, or in another language.

#### Scientific misconduct

Only articles that have not been or will not be published elsewhere will be published in the journal, excluding articles that fall under De Gruyter's Repository Policy. Multiple submissions/publications or redundant publications (i.e., republication of data already published by the same authors) will be rejected. If identified after publication, the journal reserves the right to publish a retraction note. Editors will follow COPE's Code of Conduct and implement its advice.

## **Research integrity**

The authors are responsible for all aspects of the study and will ensure that any questions regarding the accuracy and integrity of any part of the work are adequately investigated and resolved. By submitting a manuscript to *Biol Chem* the authors declare that they are the sole and intellectual authors of the work. We do not accept submissions that name Artificial Intelligence (AI) and/or Machine Learning Tools as credited author(s) on a manuscript because such tools cannot take responsibility for the submitted work and therefore cannot be considered as eligible authors. Where such tools or technologies are used as part of the design or methodology of a research study, their use should be clearly described in the Acknowledgments section. In case of doubt, the Editors reserve the right to ask the authors to submit the raw experimental data.

## Post-acceptance

## **Galley proofs**

The corresponding author of an article receives the galley proofs in electronic form to check them for editing and typesetting accuracy. Corresponding authors receive an e-mail notification ("Check your proof") with a link to the online proofreading system (Proof Central) through which they can access their galley proofs. The interface is similar to MS Word: authors can edit the text by entering their corrections directly, adding comments, and answering questions from the copy editor. If preferred, authors can also annotate and upload edits to the PDF version. All instructions for proof corrections, including deadlines, will be given in the e-mail notification to the corresponding author, along with a user guide, providing step-by-step instructions for inserting corrections.

Substantial changes to an article accepted for publication will only be considered by approval of the Editor or after additional peer review. The responsibility for proofreading lies solely with the authors. **According to De** 

Gruyter policy, once an article has been accepted, no changes to the author list and article title are allowed (except typographical errors). The De Gruyter production team is instructed to enforce this policy during the production/proof correction process.

#### **Offprints**

Electronic files of typeset articles in Adobe Acrobat PDF format are provided free of charge. The corresponding author will receive an e-mail notification when the article has been published online, along with instructions on how to access the article PDE.

## **Repository policy**

Policies for sharing published journal articles differ for subscription-based and open access articles:

## Subscription-based and hybrid journals

Authors may deposit their articles in a public repository after an embargo period of 12 months (see De Gruyter's Sharing Policy). Only the accepted author's version of the manuscript, not the PDF version of the published article, can be published:

## **Immediately**

- via their non-commercial personal website, blog or social media channels
- by updating a preprint in arXiv, RePEc, bioRxiv, ResearchSquare, etc. with the version of the accepted manuscript
- as a closed deposit via their research institute or institutional repository for internal institutional purposes or as part of an invitation-only research collaboration workgroup
- directly by providing copies to their students or to research collaborators for their personal use
- for private scholarly sharing as part of an invitation-only work group

## After an embargo period

- as open deposits to institutional or subject repositories
- to scholarly collaboration networks (SCNs).

#### Note for authors of NIH-funded research

De Gruyter acknowledges that the author of a US-agency-funded article retains the right to provide a copy of the final manuscript to agency upon acceptance for publication or thereafter, for public archiving in PubMed Central 12 months after publication in *Biol Chem*. Note that only the accepted author's version of the manuscript, not the PDF file of the published article, can be used for NIH archiving.

#### Copyright

Manuscripts submitted to subscription and hybrid journals are accepted on condition of transfer of copyright (<u>License to Publish</u>) (for U.S. government employees: to the extent transferable) to the publisher. Once the manuscript has been accepted, it may not be published elsewhere without the consent of the copyright holders.

## Open Access in hybrid journals

The author declares consent to place the article under the Creative Commons license CC-BY 4.0. In this case, the exclusive rights previously granted to the publisher will be converted into non-exclusive rights. The authors confirm that they have already acquired all necessary rights for all components of the work in the event of an open access publication. For more information, refer to paragraph 5 in the <u>License to Publish</u>.

## **Open Access and Research Gate**

Authors publishing Open Access will see their articles automatically added to their publication pages on <u>Research Gate</u>.

## **Article Processing Charges (APCs)**

Authors publishing in **hybrid journals** do not have to pay APCs if they do not wish to publish their article open access. After acceptance and before production of an article, authors can decide whether to publish their article in open access mode. Only if they decide to publish open access, APCs will apply. All articles are peer-reviewed and accepted for publication based on the quality and impact of their scientific contribution. The decision to publish open access does not affect the peer review process or the acceptance of the article. De Gruyter has <u>institutional agreements</u> in place that allow authors to publish open access articles at no cost at all or with a significant discount. For more information on De Gruyter's open access policy, please read our <u>Open Access Policies</u>.

#### Ethical conduct of research

Manuscripts must follow certain ethical guidelines to be considered for publication. These can generally be found in the <u>Publication Ethics and Malpractice Statement</u>. Accordingly, before submitting your manuscript, please make sure that you and your co-authors agree to the applicable requirements. For example, this may involve declaring and ruling out conflicts of interest or proving compliance with legal requirements related to human and animal testing. Furthermore, our <u>Code of Conduct for Publication Procedures and Ethics</u> defines the responsibility of De Gruyter as a publisher and the Editors we work with, to ensure the legitimacy and quality of our published research. Our principles are based on the guidelines of the Committee on Publication Ethics (COPE).

## Acknowledgments

Authors may wish to acknowledge individuals, working groups, institutions, etc. who provided help and support (other than financial) during research and the preparation of the manuscript (e.g., language checking, writing assistance or proof reading of the article, etc.). Individuals acknowledged are not included on the title page, as a footnote to the title or otherwise.

## Authorization for the use of human subjects - research ethics

Manuscripts that contain information on the use of humans should clearly state that the research complies with all relevant national regulations and institutional policies and has been approved by the authors' Institutional Review Board or any equivalent Committee. Copies of the guidelines and policy statements must be available for review by the Editors, if necessary. The Editors reserve the right to seek additional information or guidance from reviewers on any cases in which concerns arise. All investigations with human subjects must be conducted by following the tenets of the Declaration of Helsinki; authors must identify the Committee or Institutional Review Board approving the experiments, and provide a statement indicating approval of the research. If applicable, information on research ethics and/or approval by the Institutional Review Board should be given in the Methods section. The "Template for Ethical and Legal Declarations" file that asks you to comment on research ethics is required for submission. Make sure that the information in the manuscript matches the information in the template.

#### Authorization for the use of experimental animals – research ethics

Manuscripts that contain information on the use of animals should clearly state that the research has complied with all relevant national regulations and institutional policies and has been approved by the authors' Institutional Review Board or any equivalent Committee. Copies of the guidelines and policy statements must be available for review by the Editor, if necessary. The Editors reserve the right to seek additional information or guidance from reviewers on any cases in which concerns arise. The research using animal subjects should be conducted according to the Principles of Laboratory Animal Care and similar documents (e.g. NIH). For manuscripts reporting experiments on live vertebrates or higher invertebrates, authors must identify the Committee approving the experiments, and must confirm that all experiments were performed in accordance with relevant regulations. If applicable, information on research ethics and/or approval by the Institutional Review Board should be given in the Methods section. The "Template for Ethical and Legal Declarations" file that asks you to comment on research ethics is required for submission. Make sure that the information in the manuscript matches the information in the template.

## **Author contributions**

In view of research integrity, authorship is generally confined to an individual who has made a substantial intellectual or practical contribution to the conception or design of the project or the acquisition, analysis, or interpretation of data for the work of a publication, and/or has drafted the work or reviewed/revised it critically for important intellectual content. The individual(s) listed as author(s) must agree to be accountable for said contribution and approve of the final version. **Honorary authorship is not allowed.** Authors must declare their responsibility for the entire content of the manuscript and may indicate the individual contributions of each author, if applicable, in the "Template for Ethical and Legal Declarations" file. Make sure that the information in the manuscript matches the information in the template.

Individuals who helped or participated in certain substantive aspects of the project or work (e.g., technical services staff), but whose contributions were not of sufficient extent to be listed as co-authors, should be appropriately acknowledged, usually in an Acknowledgements section.

## **Competing interests**

A conflict of interest for a particular manuscript exists when a participant in the peer review and publication process – author, reviewer, and Editor – has ties to activities that could inappropriately influence his or her judgment, regardless of whether the judgment is actually affected. Financial relationships with industry (for example, employment, consultancies, stock ownership, honoraria, patent applications, expert testimony, grants and other funding), either directly or through immediate family, are usually considered the most important conflicts of interest. However, conflicts can occur for other reasons, such as financial support of the study, ties to health insurance, politics or other stakeholders, personal relationships, academic competition, and intellectual passion. To ensure fair and objective decision-making, authors must declare any associations that pose a conflict of interest (financial, personal or professional) in connection with the manuscript under evaluation. The conflict-of-interest statement should be given in the "Template for Ethical and Legal Declarations". If you do not have a statement to make, please insert *none declared*.

#### **Research funding**

Funding sources should be listed at the end of the manuscript, before the References, and/or indicated in the "Template for Ethical and Legal Declarations". When the study benefitted from funding through an unrestricted grant or other resources provided to a university, college, other research institution, or an individual author, state the name of the institute or organization that provided the funding along with the grant number, if applicable. If no funding was provided for the research, the default statement "none declared" will be set in place.

#### Data availability

Biol Chem requires authors to follow the <u>Data Sharing Policy</u>, which must comply with the European GDPR (General Data Protection Regulation) rules. Research data should be made widely available to the research community to demonstrate the robustness and validity of the research presented in the journal, to enable and encourage replication of the results, and to endow the community with opportunities to learn.

By publishing in the journal, authors are required to provide a data availability statement (DAS) with their articles. The DAS confirms the presence or absence of shared data. The DAS should include information on where the data supporting the findings reported in the article can be found, including, if applicable, hyperlinks to publicly archived datasets analyzed or generated during the study. If research data are not publicly available this must be stated, as well as the conditions for accessing the data. Authors are encouraged to share their data but are not required to do so. The editorial decision to publish will not be affected by whether or not authors share their research data. The DAS should be included in the mandatory "Template for Ethical and Legal Declarations".

#### **Database submissions**

All molecules described in a paper should be described in full. In the case of proteins these should include both gene name and species of origin, preferably accompanied by an Accession Number from a protein sequence database, for example UniProtKB (<a href="https://www.uniprot.org/">https://www.uniprot.org/</a>). Authors are encouraged to deposit their data in public, open access databases, formatted according to conventions of the relevant communities prior to manuscript submission, and cite database accession numbers provided in the manuscript. For example, microarray data should be deposited in either ArrayExpress (<a href="https://www.ebi.ac.uk/biostudies/arrayexpress">https://www.ebi.ac.uk/biostudies/arrayexpress</a>) or GEO (<a href="https://www.ncbi.nlm.nih.gov/geo/">https://www.ncbi.nlm.nih.gov/geo/</a>), molecular interactions in an IMEx partner database (<a href="https://www.imexconsortium.org/">https://www.ebi.ac.uk/intact/</a>), and structural data in wwPDB (<a href="https://www.wwpdb.org/">https://www.wwpdb.org/</a>).

Each voucher specimen described or mentioned must have been deposited in an appropriate institution and bear a catalogue number. New DNA sequences associated with the article must be deposited in molecular data banks (GenBank, EMBL, DDBJ). If possible, original data used in the manuscript may be deposited in an appropriate repository in a free access format.

## **Preparation of manuscripts**

## Language

All manuscripts must be written in clear and concise English. Please use either British or American English consistently. If you have reasons to doubt your proficiency with respect to spelling, grammar, etc. (e.g., because English is not your native language), then you may wish to employ – at your own expense – the services of a professional language editor.

## General format and manuscript elements

Manuscripts (including table legends, figure legends and references) should be typed double-spaced with font size 12 letters. Pages should be numbered (with the title page as 1) and have margins of 2.5 cm (1 inch) on all sides.

Footnotes in the text should be avoided; parentheses should be used instead. Full-length papers and reviews should occupy no more than ten printed pages, short communications and minireviews should not exceed five printed pages. Each full page of printed text corresponds to approximately 900 words. Please allow sufficient space for tables and illustrations within the page limit. Note that full review articles must contain a sufficient number of Figures/Tables to aid comprehensibility of the content. Full research articles should not contain more than 7 Tables or figures; short communications have a maximum of 3 tables or figures. Further tables and/or figures may be published as online-only supplementary materials.

#### Title page information

Please provide the following information on the first page of your manuscript:

#### Author names

Write at least one given and family name in full. For all other names, initial is sufficient. List authors in the order you want them to appear in the final version. Indicate the corresponding author(s) by using an asterisk "\*" after the family name(s). Author footnotes (superscript letters or numbers) to explain authorship details are not all allowed in the author line and will be converted to an author note on the first page. Kindly stick to the wording as in the examples below:

- [Full name author A] and [full name author B] contributed equally to this work.
- [Full name author A] and [full name author B] share senior authorship.
- [Full name author A] and [full name author B] share first authorship.
- Title and short title

Provide a descriptive, concise and comprehensible main title, as well as an abbreviated form of the main title (running head) with no more than 75 characters (including blanks). The short title will be displayed on the top of each page of the final version.

#### Affiliations

For the corresponding author(s) supply the following details: e-mail address, department, institution, street, city, postal code and country; for all other authors the department, institution, city, postal code and country are mandatory. Please also provide all details concerning the current institutional affiliation in case you changed affiliation during the manuscript preparation and evaluation process.

#### **Abstract**

Give a concise summary of your article in an abstract of 200 words maximum in a single paragraph. As abstracts are published separately by Abstracting and Indexing Services, please spell out abbreviations at first use and do not include footnotes, tables, figures, equations or literature references. If it is essential to use a literature citation in the abstract, full bibliographic information must be given as per journal referencing style.

## **Keywords**

Keywords are used by abstracting and indexing services as well as search engines to facilitate finding your paper. Together with the abstract of your paper, they are a key tool enabling readers to find your paper and for increasing citations. Supply 3–6 specific keywords in alphabetical order and lower case, separated by semicolon.

#### **Sections**

Full-length papers should be organized into title page, abstract, keywords, introduction, results, discussion, materials and methods, acknowledgments, references, tables and figure legends. Main sections should be numbered with Arabic numerals (1., 2., 3. etc.); lower-level sections should be assigned numbers as follows: 1.1, 2.1, 2.1.1. etc. Sections should be labeled with headings in a consistent format and with a clear hierarchy of section headings. Limit your subsections to a maximum of four levels. Short communications should be subdivided into an abstract, keywords, and a single section of main text without headings. Experimental procedures should be described in legends to figures or footnotes to tables. Acknowledgments and references should be presented as in full-length papers.

#### References

For literature citations authors are encouraged to rely as far as possible upon articles published in primary research journals. Unpublished results and personal communications should be cited as such within the text (but

not included in the references list); personal communications must be substantiated by a letter of permission. Meeting abstracts may not be cited.

Within the text references should be cited by author and date (Harvard style); et al. should be used if there are more than two authors. At the end of the text citations should be listed in alphabetical order and should contain complete bibliographic information. The number of references should not exceed 150 for reviews or 30 for minireviews. All literature references given in the references list must be mentioned in the text, and *vice versa*. Detailed guidelines and examples for formatting the cited literature are given at the end of this document.

## Figures and figure captions

Graphs, line drawings, photographs, schemes, diagrams, etc. may be used to illustrate your findings. Publication of color figures is provided free of charge in both online and print editions. The publication quality always depends directly on the quality and size of the delivered data.

Please label the illustrations as "Figure" ("Scheme" should be avoided). Each figure should be uploaded separately as .jpg, .eps, .png or .tiff file. Images should have a minimum resolution of 300 dpi (color or black-white pixel graphics/half-tone images) or 600 dpi (combination of pixel graphic and line drawings) in the intended size. Use patterning or colors instead of grey scales in bar graphs as faint shading may be lost upon reproduction.

Figures should be numbered consecutively using Arabic numerals (starting with 1) throughout the text. If you include multi-part figures, make sure to label all part figures by using uppercase letters. Ensure that all figures are explicitly referred to in the text. Do not end the text immediately preceding the suggested positioning of a figure with a colon, and avoid expressions such as "in Figure 1 below/above", as the exact positioning of these elements cannot be determined until the manuscript has been typeset. Provide a concise and self-explanatory caption for each figure. In case of multi-panel figures, provide a main caption as well as legends for the individual figure panels. The key to the symbols depicted in the figures should be included in the figure itself, where possible. Otherwise, include it in the caption/legends. The caption itself must not be included in the figure. Please make sure that letters, numbers, symbols, text, etc. shown in the figure are clear, easy to read (not below 6 pt, preferably in Arial or Helvetica font) and uniform in style.

For figures containing fitted images (for example gel pictures) authors are requested to submit the uncropped pictures as "Supplementary File for Review" (file designation for upload) in order to facilitate the peer reviewing process. The Editors reserve the right to stall the editorial processing if such material is missing but deemed necessary for a comprehensive evaluation of the work.

It is the authors' responsibility to use images that do not infringe on any copyrights, performing rights, trademark rights, personal rights or any other third-party rights or are otherwise unlawful. In case graphic material is used for which neither of the authors holds the copyright, obtain written permission for using such material from the copyright holder or the Copyright Clearance Center (<a href="https://www.copyright.com/">https://www.copyright.com/</a>) prior to submission of the final manuscript version. It is the sole responsibility of the authors to obtain proper permission for the use of copyrighted material.

#### Tables and table captions

Number tables consecutively using Arabic numerals. Tables should be provided in an editable source format (MS Word, LaTeX). Do not submit tables as graphical image or Excel files. Provide a short descriptive title, column heads, and (if necessary) footnotes to make each table self-explanatory. In column heads, separate units with a comma and use parentheses or square brackets for additional measures (e.g., %, range, etc.). Use footnotes in alphabetical order (a, b, c, etc.) to give emphasis or further information. Expand abbreviations used in tables in footnotes. In case bold type or italics formatting is used to highlight information, please explain their meaning.

#### **Abbreviations**

The use of abbreviations and acronyms is permitted given that they are expanded in full when used for the first time with the abbreviation in parentheses (applies to abstract and main text). Please use them consistently thereafter. All non-standard abbreviations may be listed alphabetically after the keywords (running text, no Table).

#### **Equations and symbols**

Equations should be well-aligned and not crowded. Use only Latin and Greek alphabets. Avoid complicated superscripts and subscripts by introducing new symbols. Avoid repetition of a complicated expression by representing it with a symbol. For MS Word submissions create equations using the Microsoft equation editor or a corresponding add-on. Do not submit mathematical equations as images, but as editable text. Number displayed equations consecutively with Arabic numerals (if referred to in the text).

#### Scientific names and non-abbreviated Latin expressions

Gene acronyms, alleles, genus, species, and non-abbreviated Latin expressions should be written in italic font type.

Capitalize the first letter of the genus, but not the species. Format all binomial names in italics. After the first use, genus names may be abbreviated to a first initial. For genus names starting with the same letter differentiate by including the second letter.

#### **Nomenclature**

With respect to biochemical terminology *Biol Chem* will follow the rules laid down by the IUPAC-IUB Commission on Biochemical Nomenclature, as given in Biochemical Nomenclature and Related Documents, published by the Biochemical Society, U.K. Enzyme names should be in accordance with the recommendations of the IUPAC-IUB Commission on Biochemical Nomenclature.

#### Units

Use SI units consistently. For more information, please visit https://www.bipm.org/en/home

#### **Audio and Video**

For all examples connected to an audio/video recording, it is possible to supply audio/video clips. Deliver these clips as separate files and do not embed them directly into the manuscript. Name your clips using the following convention: e.g., audio-1-smith.MP3, video-1-smith.MP4, [media]-[identifier]-[author-family-name].[extension]. Indicate the position in the article by placing a marker as follows: [associated audio-1-smith.wav with example (1)]. Provide a short caption for each media file and number them consecutively. Any other media files can be included as part of the supplementary material. File naming: audiosupplement-1-smith.MP3, [media.supplement]-[identifier]-[author-family-name].[extension]. The following formats are preferred: audio files in MP3 (at least 16 bit) and video files in MP4 (at least a height of 480 pixels and a frame rate of 25). However, other common formats are also permitted.

## **Appendices**

Use appendices for information that supports your findings but is not essential for the understanding of your paper (e.g., extensive mathematical proofs, tables, graphics, etc.). Cite appendices within the main text. Tables and figures in the appendix should be numbered consecutively as follows: Figure A.1, Table A.1, Figure A.2, Table A.2, etc. The appendix is placed at the end of the main text before the reference list.

## Supplementary material

Supplementary material, which may offer further information on your work but does not belong to the core part of the article, will not be part of the typeset article PDF. The material will be made available as a separate download in the online version of the article. Supplementary material may contain protocols, code samples, datasets, extensive tables, additional figures, multimedia files (audio, video, animations), etc. If the manuscript is accepted, supplementary material will be referenced in the print version, but will be published online only.

Please provide supplementary material data as separate file(s) of no more than 10 MB per file during submission. Note that the material should be publication-ready (not in track-changes mode), as it will not be typeset, but published exactly as supplied. Within the text, the supplementary material must be cited consecutively and be referred to as supplementary material data (e.g., see Supplementary Material, Figure 1, or Figure S1, Table S1, etc.).

#### Author short biography and photograph

Authors of reviews or minireviews may provide a portrait photograph and a short scientific CV (80 words max. per author, written in the 3<sup>rd</sup> person singular). This information will be published in the article after the references section. Please use the appropriate "file designation" terms for the CV text file(s) and author photograph(s) during online submission. For articles with more than five authors, the bionotes are restricted to five. Note that during production/article proofing no additional author photos/CVs are permitted.

## Please contact the Editorial Office for any further questions:

e-mail: biol.chem.editorial@degruyter.com; Tel.: +49-30-26005176. We will do our best to assist you.

## **Biological Chemistry Referencing Style**

In-text citation			
	Direct citation	Indirect citation	
Single author	Baker (2015)	(Baker 2015)	
Two authors	Borgonovi and Burns (2015)	(Borgonovi and Burns 2015)	
More than two authors	Martin et al. (2014)	(Martin et al. 2014)	
Series of refe-	Series of references Zabal et al. (2014) and Mohadjer et al. (2013a)	Alphabetical order	
rences		(Mohadjer et al. 2013a; Zabal et al. 2014).	
Same author group with dif- ferent years	Smith et al. (1995, 1997)	(Smith et al., 1995, 1997)	
Same author (group) with same year	Lawrence and David (2009a,b)	(Lawrence and David 2009a,b)	
References list			
Reference type	Example		
Reference list order	Alphabetical order		
1. Journal	Allis, C.D. and Jenuwein, T. (2016). The molecular hallmarks of epigenetic control. <i>Nat. Rev. Genet.</i> 17: 487–500.		
2. Journal with supplement	Dahlmann, B. (2007). Role of proteasomes in disease. <i>BMC Biochem</i> . 8 (Suppl. 1): S3.		
3. et al. usage (more than ten authors follo- wed by et al.)	Porodko, A., Cirnski, A., Petrov, D., Raab, T., Paireder, M., Mayer, B., Maresch, D., Nika, L., Biniossek, M.L., Gallois, P., et al. (2018). The two cathepsin B-like proteases of <i>Arabidopsis thaliana</i> are closely related enzymes with discrete endopeptidase and carboxydipeptidase activities. <i>Biol. Chem.</i> 399: 1223–1235.		
4. Epub ahead of print	Yamauchi, K., Iwasaki, Shio., and Kawakami, Y. (2019). Redox equilibrium of serum apolipoprotein E3: a buffering effect of disulfide-linked complexes against oxidative stress on apolipoprotein E3-containing lipoproteins. <i>Biosci. Rep.</i> , DOI: 10.1042/BSR20190184 (Epub ahead of print).		
5. Book/ mono- graph	Andreasen, N.C. (2001). Brave new brain: conquering mental illness in the era of the genome. Oxford University Press, Oxford.		
6. Edited book	Hauser, H., Wagner, R. (Eds.) (2014). <i>Animal Cell Biotechnology</i> . De Gruyter, Berlin.		
7. Edited book with chapter title	Schuchman, E.H. and Desnick, R.J. (2001). Niemann-Pick disease types A and B: Sphingomyelinase deficiencies. In: Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, D. (Eds.). <i>The Metabolic and Molecular Bases of Inherited Disease</i> . McGraw-Hill, New York, pp. 3589–3610.		
8. Electronic publication (Available at)	Cooper, G.M. (2000). The Cell - A Molecular Approach, 2nd edition. Sinauer Associates, Available at: <a href="https://www.ncbi.nlm.nih.gov/books/NBK9839">https://www.ncbi.nlm.nih.gov/books/NBK9839</a> .		
9. Thesis/Dis- sertation	Radchenko, D. (2018). Cellular signaling pathways in the filamentous fungus Sordaria macrospora: molecular genetic analysis of the STRIPAK-associated germinal center kinase SmKIN3 in developmental processes, Ph.D. thesis. Bochum, Ruhr-University Bochum.		